Salles Évila Lopes, Emami Naeini Sahar, Bhandari Bidhan, Khodadadi Hesam, Threlkeld Edie, Rezaee Sholeh, Meeks William, Meeks Avery, Awe Aderemi, El-Marakby Ahmed, Yu Jack C, Wang Lei P, Baban Babak
Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA 30912, USA.
Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Curr Issues Mol Biol. 2022 Dec 30;45(1):223-232. doi: 10.3390/cimb45010017.
Elabela is a component of the apelinergic system and may exert a cardioprotective role by regulating the innate immune responses. Innate lymphoid cells (ILCs) have a significant role in initiating and progressing immune-inflammatory responses. While ILCs have been intensively investigated during the last decade, little is known about their relationship with the apelinergic system and their cardiac diversity in a gender-based paradigm. In this study, we investigated the polarization of cardiac ILCs by Elabela in males versus females in a mouse model. Using flow cytometry and immunohistochemistry analyses, we showed a potential interplay between Elabela and cardiac ILCs and whether such interactions depend on sexual dimorphism. Our findings showed, for the first time, that Elabela is expressed by cardiac ILCs, and its expression is higher in females' ILC class 3 (ILC3s) compared to males. Females had higher frequencies of ILC1s, and Elabela was able to suppress T-cell activation and the expression of co-stimulatory CD28 in a mixed lymphocyte reaction assay (MLR). In conclusion, our results suggest, for the first time, a protective role for Elabela through its interplay with ILCs and that it can be used as an immunotherapeutic target in the treatment of cardiovascular disorders in a gender-based fashion.
艾拉贝拉是阿片肽能系统的一个组成部分,可能通过调节先天性免疫反应发挥心脏保护作用。先天性淋巴细胞(ILCs)在启动和推进免疫炎症反应中起重要作用。尽管在过去十年中对ILCs进行了深入研究,但对于它们与阿片肽能系统的关系以及在基于性别的模式下其心脏多样性知之甚少。在本研究中,我们在小鼠模型中研究了艾拉贝拉对雄性和雌性心脏ILCs极化的影响。通过流式细胞术和免疫组织化学分析,我们展示了艾拉贝拉与心脏ILCs之间潜在的相互作用以及这种相互作用是否取决于性别差异。我们的研究结果首次表明,心脏ILCs表达艾拉贝拉,并且与雄性相比,其在雌性3类ILCs(ILC3s)中的表达更高。雌性的ILC1s频率更高,并且在混合淋巴细胞反应试验(MLR)中,艾拉贝拉能够抑制T细胞活化和共刺激分子CD28的表达。总之,我们的结果首次表明,艾拉贝拉通过与ILCs的相互作用发挥保护作用,并且它可以作为一种免疫治疗靶点,以基于性别的方式用于治疗心血管疾病。